## **Supporting Information**

## **SI Materials and Methods**

**Plasma IgG adsorptions on SF162 gp120- and SF162 gp120**<sub>D368R</sub>-coated beads. Plasma adsorptions were performed as previously described (1, 3), with some modifications, and the flow of the adsorptions is outlined in Figure S1. Briefly, total IgG was isolated by protein A chromatography (Pierce, Rockford II, USA) from VC10042 plasma drawn 22 years post-infection. The purified total IgG was serially adsorbed onto SF162 gp120-coated beads (MyOne Tosylactivated Dynabeads, Invitrogen, Carlsbad, CA, USA), and the flow through collected. The antibodies bound to the gp120 coated beads were eluted by vortexing in increasingly acidic 0.1M glycine solutions, followed by buffer exchange into PBS. The anti-gp120 Ab fraction was then serially adsorbed onto SF162 gp120<sub>D368R</sub>-coupled beads to remove Abs that do not bind the CD4-BS. Each fraction described above was tested for residual neutralizing activity against 4 clade B, 3 clade C, and 2 clade A isolates in the TZM-bl neutralization assay. The depleted total IgG and the gp120<sub>D368R</sub> depleted anti-gp120 fractions were tested for the presence of anti-CD4-BS antibodies, and the absence of non-CD4-BS gp120 and SF162 gp120<sub>D368R</sub>.

<u>Figure S1</u>			
HIV -	+ total lgG 人イ ト イ	+ gp120 ↓	$\alpha$ -gp120 Abs $\Rightarrow$ $\Rightarrow$ $\Rightarrow$ $\Rightarrow$ $\Rightarrow$ $\Rightarrow$ $gp120_{D368R}$ mutant $\downarrow$
		λ.	CD4-BS Abs
		Column A gp120-depleted lgG	Column B: gp120 <sub>D368R</sub> flow through Abs (CD4-BS)
		$\downarrow$	$\downarrow$
		% Residual neutralizing	
		neutralizing activity	activity of anti-gp120
		after depletion with	NAbs after depletion
		gp120	with gp120 <sub>D368R</sub>
Clade	e Isolate		
	YU2	8.22	97.43
	QH0692	21.11	94.68
	TRO.11	14.08	96.48
Р	JR-FL	11.09	98.85
В	SF162.LS	7.86	97.39
	ADA	13.35	86.61
	5768.4	22.22	94.97
	REJO4541.67	31.05	94.96
C	ZM249M.PL1	13.26	74.28
	Du156.12	27.41	97.81
	Du422.1	7.48	80.44
	Q461.d1	16.94	88.04
A	Q769.h5	30.16	95.29

**Figure S1.** Contribution of anti-CD4-BS NAbs to the overall neutralizing potential of plasma isolated from subject VC10042. IgG was first isolated from heat-treated plasma, and then antibodies that bind to gp120 were adsorbed onto SF162 gp120-coated magnetic beads. After 6 rounds of serial adsorption with gp120-coated beads, the flow through was tested for residual neutralizing activity against 4 clade B, 3 clade C, and 2 clade A isolates. The values in the first column represent the percent residual neutralizing activity against each isolate after depletion with gp120. Anti-gp120 antibodies were eluted from the SF162 gp120-coated magnetic beads, and then serially adsorbed onto magnetic beads coated with SF162 gp120<sub>D368R</sub> to remove antibodies that do not bind to the CD4-BS. The anti-gp120 antibodies and the gp120<sub>D368R</sub> flow through (containing the anti-CD4-BS NAbs) were tested against the 9 isolates described above. The percent residual neutralizing activity of the anti-gp120 antibody fraction after depletion with gp120<sub>D368R</sub> (the neutralizing activity due to anti-CD4-BS NAbs) is shown in the second column. All depletions were confirmed by Luminex assay against SF162 gp120 and SF162 gp120<sub>D368R</sub>.



**Figure S2.** A) Log10 viral RNA copies per ml of blood during the time of observation. B) The number of CD4+ and CD8+ T cells per microliter of blood during observation.

	sig 10	mal peptide		→ gp120	30 50	60	0 70	0 80	90
Con Cl. B 10042.48 10042.72 10042.101 10042.113 10042.205	 MRVKGIRKNY MRVKEIRKSY MRVKEIRKSY MRVKEIRKSY MRVKEIRKSY	I QHLWRWGTML QHLWKWGIML QHLWKWGIML QHLWKWGIML QHLWKWGIML	I LGMLMICSAA FGMLMICSAT FGMLMICSAT FGMLMICSAT FGMLMICSAT	I EKLWVTVYYG RQLWVTVYYG RQLWVTVYYG RQLWVTVYYG RQLWVTVYYG	I VPVWKEATTT VPVWKEANTT VPVWKEANTT VPVWKEANTT VPVWKEANTT	I LFCASDAKAY LFCASDAKAY LFCASDAKAY LFCASDAKAY LFCASDAKAY	I DTEVHNVWAT DTEVHNIWAT DTEVHNIWAT DTEVHNIWAT DTEVHNIWAT	I HACVPTDPNP HACVPTDPNP HACVPTDPNP HACVPTDPNP HACVPTDPNP	I QEVVLINVIE HEVELKNVIE HEVELKNVIE HEVELKNVIE
	• 100	110	120	. 130	0 140	V1- 150	0 160	) 170	180
Con C1. B 10042.48 10042.72 10042.101 10042.113 10042.205	I N FNMWENNMV N FNMWENNMV N FNMWENNMV N FNMWENNMV N FNMWENNMV	I EQMHEDIISL EQMHEDIISL EQMHEDIISL EQMHEDIISL EQMHEDIISL	I WDQSLKPCVK WDQSLKPCVK WDQSLKPCVK WDQSLKPCVK WDQSLKPCVK	I LTPLCVTLNC LTPLCVTLNC LTPLCVTLNC LTPLCVTLNC LTPLCVTLNC	I TDLMNAT AD-WNATKAN AD-WNATKAN AD-WNATKAN AD-WNATKAN AD-WNATKAN	I NT-NTTI NTTNTTSTNT NTTNTTSTNT NTTNTTSTNT NTTNTTSTNT	IY-RWR TSDRVKTMEG TSDRVKTMEG TSDRVKTMEG TSDRVKTMEG TSDRVKTMEG	I GEIKNCSFNI GEVKNCSFNI GEVKNCSFNI GEVKNCSFNI GEVKNCSFNI	I TTSIRDKVQK TASMADKRQK TASMADKRQK TASMADKRQK TASMADKRQK TASMADKRQK
		-v2							
Con Cl. B 10042.48 10042.72 10042.101 10042.113 10042.205	I EYALFYKLDV EYALFYKLDV EYALFYKLDV EYALFYKLDV EYALFYKLDV	I VPIDND4TSY EPIDNS3TSY EPIDNS3TSY EPIDNS3TSY EPIDNS3TSY EPIDNS3TSY	I RLISCNTSVI RLINCNTSVL RLINCNTSVL RLINCNTSVL RLINCNTSVL	I TQACPKVSFE TQACPKVSFE TQACPKVSFE TQACPKVSFE TQACPKVSFE	I PIPIHYCAPA PIPIHYCAPA PIPIHYCAPA PIPIHYCAPA PIPIHYCAPA	GFAILKCNDK GFAILKCNEK GFAILKCNEK GFAILKCNEK GFAILKCNEK	KFNGTGPCIN KFNGTGPCIN KFNGTGPCIN KFNGTGPCIN KFNGTGPCIN	VSTVQCTHGI VSTVQCTHGI VSTVQCTHGI VSTVQCTHGI VSTVQCTHGI VSTVQCTHGI	RPVVSTQLLL RPVVSTHLLL RPVVSTHLLL RPVVSTHLLL RPVVSTHLLL RPVVSTHLLL
	280		•• 300	310	320	330	340	350	360
Con Cl. B 10042.48 10042.72 10042.101 10042.113 10042.205	I NGSLAEEGVV NGSLAEEGVV NGSLAEEGVV NGSLAEEGVV NGSLAEEGVV	IRSENFIDNA IRSANFJDND IRSANFJDND IRSANFJDND IRSANFJDND IRSANFJDND	KTIIVQLNES DNIIVQLNDS DNIIVQLNDS DNIIVQLNDS DNIIVQLNDS DNIIVQLNDS	I VEINCTRPNN VTISCIRPGN VTISCIRPGN VTISCIRPGN VTISCIRPGN	I NTRKSIHIGP NTRKSIHIGP NTRKSIHIGP NTRKSIHIGP	 GRAFYTTGEI GRAFYATGEI GRAFYATGEI GRAFYATGEI GRAFYATGEI	I IGDIRQAHCN IGDIRQAHCN IGDIRQAHCN IGDIRQAHCN IGDIRQAHCN	I ISRAKWNNTL LSRAGWSNTL LSRAGWSNTL LSRAGWSNTL LSRAGWSNTL	I KQIVKLLREQ QQIVEALKEQ QQIVEALKEQ QQIVEALKEQ QQIVEALKEQ
	370		390	400	V4	420	430		450
Con Cl. B 10042.48 10042.72 10042.101 10042.113	 FGN-KTIVFN YGNNKTIVFK YGNNKTIVFK YGNNKTIVFK	QSSGGDPEIV PHAGGDPEVE PHAGGDPEVE PHAGGDPEVE PHAGGDPEVE	<ul> <li>HISFNCGGEF</li> <li>RHIFNCGGEF</li> <li>RHIFNCGGEF</li> <li>RHIFNCGGEF</li> </ul>	 FYCNTTQLF- FYCNTTQLFT FYCNTTQLFT FYCNTTQLFT FYCNTTQLFT	 -NSTWNGT WNDTELINGT WNDTELINGT WNDTELINGT	 WNNTEGN- WNSTEGSDND WNSTEGSDND WNSTEGSDND	-ITLPCRIEQ TIILPCRIEQ TIILPCRIEQ TIILPCRIEQ TIILPCRIEQ TIILPCRIEQ	IINHWQEVGK IINRWQEVGK IINRWQEVGK IINRWQEVGK IINRWQEVGK	AMYAPPIRGQ AMYAPPIRGQ AMYAPPIRGQ AMYAPPIRGQ AMYAPPIRGQ
10042.205	YGNNETIVFE	PHAGGDPEVE	RHIFNCGGEF	FYCWTTQLFT	WNDTELINGT	WNSTEGSDND	TIILPCRIKQ	IINRWQEVGK	AMYAPPIRGQ
10042.205	YGNNKTIVFK	PHAGGDPEVE	RHIFNCGGEF	FYCHTTQLFT	WNDTELINGT	WNSTEGSDND	TIILPCRIKQ	IINRWQEVGK	AMYAPPIRGQ
Con Cl. B 10042.205 10042.48 10042.72 10042.101 10042.113 10042.205	YGNNKTIVFK 460 I IRCSSNITGL IRCSSNITGL IRCSSNITGL IRCSSNITGL IRCSSNITGL	PHACGDPEVE LLTRDGN-N ILTRDGNTS ILTRDGNTS ILTRDGNTS ILTRDGNTS ILTRDGNTS	RHIFNCGGEF ETEIFR ETKIDIETFR ETKIDIETFR ETKIDIETFR ETKIDIETFR	FYCNTTQLFT PGGGDMRDNW PGGGNMRDNW PGGGNMRDNW PGGGNMRDNW PGGGNMRDNW	WNDTELINGT SOU RSELYKYKVV RSELYKYKVV RSELYKYKVV RSELYKYKVV RSELYKYKVV	WNSTEGSDND SIG KIEPLGVAPT RIEPLGVAPT RIEPLGVAPT RIEPLGVAPT	TIILPCRIEQ SZC I KAKRRVVQRE EAKRRVVQRE EAKRRVVQRE EAKRRVVQRE EAKRRVVQRE EAKRRVVQRE	IINRWQEVGK 530 530 1 KRAVGIGALF KRAVGIGALF KRAVGIGALF KRAVGIGALF	AMYAPÞIRGQ 540 IGFLGAGST LGFLGAGST LGFLGAGST LGFLGAGST LGFLGAGST
10042.205 Con Cl. B 10042.48 10042.72 10042.101 10042.113 10042.205	YGNNKTIVFK 4600 I IRCSSNITGL IRCSSNITGL IRCSSNITGL IRCSSNITGL IRCSSNITGL S500	PHAGGDPEVE VS LLTRDGNTS ILTRDGNTS ILTRDGNTS ILTRDGNTS ILTRDGNTS ILTRDGNTS	RHIFNCGGEF ETEIFR ETKIDIETFR ETKIDIETFR ETKIDIETFR ETKIDIETFR ETKIDIETFR	FYCWTQLFT PGGGDMRDNW PGGGNMRDNW PGGGNMRDNW PGGGNMRDNW PGGGNMRDNW PGGGNMRDNW	WNDTELINGT O 500 I RSELYKYKVV RSELYKYKVV RSELYKYKVV RSELYKYKVV RSELYKYKVV RSELYKYKVV RSELYKYKVV	WNSTEGSDND SIG KIEPLGVAPT RIEPLGVAPT RIEPLGVAPT RIEPLGVAPT RIEPLGVAPT RIEPLGVAPT RIEPLGVAPT	TIILPCRIEQ 520 KAKRRVVQE EAKRRVVQE EAKRRVVQE EAKRRVVQE EAKRRVVQE EAKRRVVQE EAKRRVVQE	IINRWQEVGK	AMYAPPIRGQ 540 LGFLGAAGST LGFLGAAGST LGFLGAAGST LGFLGAAGST LGFLGAAGST LGFLGAAGST
Con C1. B 10042.205 10042.48 10042.72 10042.101 10042.101 10042.205 Con C1. B 10042.48 10042.72 10042.101 10042.205	YGNNKTIVFK 4600 IRCSSNITGL IRCSSNITGL IRCSSNITGL IRCSSNITGL IRCSSNITGL S500 MGAASMLTY MGAASMLTY MGAASILITY MGAASILITY	PHAGGDPEVE V LLTRDGN-N LLTRDGNTS ILTRDGNTS ILTRDGNTS ILTRDGNTS ILTRDGNTS ILTRDGNTS ILTRDGNTS OARQLLSGIV OARQLLSGIV QARQLLSGIV QARQLLSGIV	RHIFNCGGEF ETEIFR ETKIDIETFR ETKIDIETFR ETKIDIETFR ETKIDIETFR OQONNLLRAI OQONNLLRAI QQONNLLRAI QQONNLLRAI	PYCHTTQLFT PGGSDMEDNW PGGSNM	WNDTELINGT	WNSTEGSDND SIG KIEPLGVAPT RIEPLGVAPT RIEPLGVAPT RIEPLGVAPT RIEPLGVAPT P VLAVERVIE VLAVERVI	TIILPCRIRQ SIZE AKRRVVQRE EAKRRVVQRE EAKRRVVQRE EAKRRVVQRE EAKRRVVQRE EAKRRVVQRE CAKRVVQRE CAKRVVQRE CAKRVVRE CAKRRVVRE CAKRRVVRE CAKRRVVRE CAKRVVRE	IINRWQEVGR IINRWQEVGR S33 KRAVGIGALF K	AMYAPPIRGQ 50540 LGFLGAAGST LGFLGAAGST LGFLGAAGST LGFLGAAGST LGFLGAAGST LGFLGAAGST LGFLGAAGST LGFLGAAGST LGFLGAAGST WINSKSHIKS WINSKSHIKS WINSKSHIKS WINSKSHIKS WINSKSHIKS WINSKSHIKS
Con Cl. B 10042.205 10042.48 10042.72 10042.101 10042.101 10042.205 Con Cl. B 10042.48 10042.205	YGNNKTIVFK 460 IRCSSNITGL I	PHAGGDPEVE	RHIFNCGGEF ETEIFR ETKIDIETFR ETKIDIETFR ETKIDIETFR ETKIDIETFR OQONNLLRAI QQONNLLRAI QQONNLLRAI QQONNLLRAI	PYCNTTQLFT PGGDMDDNW PGGDNMDNW PGGSNMED	WNDTELINGT 0 500 1 RSELYKYKVV RSELYKYKVV RSELYKYKVV RSELYKYKVV RSELYKYKVV RSELYKYKVV 0 590 1 VWGIKQLQAR VWGIKQLQAR VWGIKQLQAR 0 660	WNSTEGSDND SIG KIEPLGVAPT KIEPLGVAPT RIEPLGVAPT RIEPLGVAPT RIEPLGVAPT RIEPLGVAPT VLAVERVIND V	TIILPCRIRQ TIILPCRIRQ KAKRRVVQRE EAKRRVVQRE EAKRRVVQRE EAKRRVVQRE EAKRRVVQRE EAKRRVVQRE CALLGIWGCS QCLLGIWGCS QCLLGIWGCS QCLLGIWGCS QCLLGIWGCS QCLLGIWGCS QCLLGIWGCS	IINRWQEVGR IINRWQEVGR S30 KRAVGIGALF K	AMYAPPIRGQ 540 LGFLGAAGST LGFLGAAGST LGFLGAAGST LGFLGAAGST LGFLGAAGST LGFLGAAGST LGFLGAAGST LGFLGAAGST LGFLGAAGST WINSSMSHIKS WINSSMSHIKS WINSSMSHIKS WINSSMSHIKS WINSSMSHIKS WINSSMSHIKS WINSSMSHIKS
Con C1. B 10042.205 10042.48 10042.72 10042.101 10042.103 10042.205 Con C1. B 10042.205 Con C1. B 10042.48 10042.205 Con C1. B 10042.48 10042.205	YGNNKTIVFK 460 IRCSSNITGL I	PHAGGDPEVE V V V V V V V V V V V V V	RHIFNCGGEF ETEIFR ETKIDIETFR ETKIDIETFR ETKIDIETFR ETKIDIETFR OQONNLEAI QOONNLEAI QOONNLEAI QOONNLEAI OQONNLEAI OQONNLEAI COONNLEAI C	PYCHTTQLFT PGGSDMEDNW PGGSDMEDNW PGGSDMEDNW PGGSDMEDNW PGGSDMEDNW PGGSDMEDNW PGGSDMEDNW PGGSDMEDNW PGGSDMEDNW PGGSDMEDNW PGGSDMEDNW PGGSDMEDNW PGGSDMEDNW PGGSDMEDNW PGGSDMEDNW PGGSDMEDNW PGGSDMEDNW PGGSDMENEQ SONQGENEQ SONQGENEQ SONQGENEQ	WNDTELINGT NDTELINGT RSELYKYKVV RSELYKYKVV RSELYKYKVV RSELYKYKVV RSELYKYKVV SSELYKYKVV SSELYKYKVV SSELYKYKVV SSELYKYKVV SSELYKYKVV MGIKQLQAR VWGIKQLQAR VWGIKQLQAR VWGIKQLQAR O 6 6 6 0 0 0 0 0 0 0 0 0 0 0 0 0	WNSTEGSDND I KIEPLGVAPT RIEPLGVAPT RIEPLGVAPT RIEPLGVAPT RIEPLGVAPT RIEPLGVAPT VLAVERYLAD 0 0 0 0 0 0 0 0 0 0 0 0 0	TIILPCRIRQ TIILPCRIRQ KAKRRVVQRE EAKRRVVQRE EAKRRVVQRE EAKRRVVQRE EAKRRVVQRE EAKRRVVQRE EAKRRVVQRE EAKRRVVQRE CALLGIWGCS QCLLGIWGCS QCLLGIWGCS QCLLGIWGCS QCLLGIWGCS QCLLGIWGCS QCLLGIWGCS QCLLGIWGCS QCLLGIWGCS QCLLGIWGCS QCLLGIWGCS QCLLGIWGCS QCLLGIWGCS CALLGI	IIINRWQEVGR IINRWQEVGR RAVGIGALF KRAVGIGALF KRAVGIGALF KRAVGIGALF KRAVGIGALF KRAVGIGALF KRAVGIGALF KRAVGIGALF KRAVGIGALF KRAVGIGALF GKLICTTAVP GKLICTTAVP GKLICTTAVP GKLICTTAVP GKLICTTAVP GKLICTTAVP GKLICTTAVP GKLICTTAVP GKLICTTAVP GKLICTTAVP GKLICTTAVP GKLICTTAVP GKLICTTAVP GKLICTTAVP GKLICTTAVP GKLICTTAVP	AMYAPPIRGQ 5 540 1 LGFLGAAGST LGFLGAAGS
Con C1. B 10042.48 10042.48 10042.101 10042.101 10042.103 10042.205 Con C1. B 10042.48 10042.205 Con C1. B 10042.48 10042.205	YGNNKTIVFK 460 IRCSSNITGL I	PHAGGDPEVE 4V5 LLTADGSN-N ILTADGSNTS I	RHIFNCGGEF ETEIFR ETKIDIETFR ETKIDIETFR ETKIDIETFR ETKIDIETFR OQONNLLRAI QQONNLLRAI QQONNLBAI QQONNLBAI QQONNLBAI OQONNLBAI QQONNLBAI GUIYNLEE TGLIYNLEE TGLIYNLEE TGLIYNLEE TGLIYNLEE	PYCHTTQLFT PGGSDMEDNW PGGSDMENNW PGGSDM	WNDTELINGT NRSELYKYKVV RSELYKYKVV RSELYKYKVV RSELYKYKVV RSELYKYKVV RSELYKYKVV O O UWGIKQLQAR VWGIKQLQAR VWGIKQLQAR VWGIKQLQAR UWGIKQLQAR O 6 0 1 ELLELDRWAS DLIALDRWDS DLIALDRWDS DLIALDRWDS 0 0 770	WNSTEGSDND I KIEPLGVAPT RIEPLGVAPT RIEPLGVAPT RIEPLGVAPT RIEPLGVAPT RIEPLGVAPT RIEPLGVAPT VLAVERVIEN O O O O O O O O O O O O O	TIILPCRIRQ TIILPCRIRQ CARREVVORE EARREVVORE EARREVVORE EARREVVORE EARREVVORE EARREVVORE EARREVVORE EARREVVORE EARREVVORE EARREVVORE EARREVVORE EARREVVORE EARREVVORE EARREVORE CARDEN OCLLGINGCS OCL OCL OCL OCL OCL OCL OCL OCL	IINRMQEVGR IINRMQEVGR S33 KRAVGIGALF KRAVGIGALF KRAVGIGALF KRAVGIGALF KRAVGIGALF KRAVGIGALF KRAVGIGALF KRAVGIGALF KRAVGIGALF VGGLICTAVP GKLICTTAVP GKLICTTAVP GKLICTTAVP GKLICTTAVP GKLICTTAVP GKLICTTAVP GKLICTTAVP GKLICTTAVP GKLICTTAVP GKLICTAVP GKLICTAVP GKLICTAVP GKLICTAVP MGGLIGLRIV VGGLIGLRIV VGGLIGLRIV VGGLIGLRIV VGGLIGLRIV	AMYAPPIRGQ 540 1 LGFLGAAGST
Con C1. B 10042.205 10042.48 10042.211 10042.101 10042.205 Con C1. B 10042.48 10042.205 Con C1. B 10042.48 10042.205 Con C1. B 10042.48 10042.72 10042.101 10042.205	YGNNKTIVFK 460 IRCSSNITGL IRCSSNITG IRCSSNITG IRCSSNIT IRCSSNIT IRCSSNITG	PHAGGDPEVE VI LLTRDGNTS LLTRDGNTS ILTRDG	RHIFNCGGEF ETEIFR ETKIDIETFR ETKIDIETFR ETKIDIETFR ETKIDIETFR ETKIDIETFR ETKIDIETFR ETKIDIETFR ETKIDIETFR ETKIDIETFR OQONNLERAI QOONNLERAI QOONNLERAI QOONNLERAI QOONNLERAI QOONNLERAI GUONNLERAI COONNLE	PYCHTTQLFT PGGEDMEDNW PGGENMEDNW PGGENMEDNW PGGENMEDNW PGGENMEDNW PGGENMEDNW PGGENMEDNW PGGENMEDNW PGGENMEDNW PGGENMEDNW PGGENMEDNW PGGENMEDNW PGGENMEDNW PGGENELQLT EAQOHLLQLT EAQOHLLQLT EAQOHLLQLT EAQOHLLQLT EAQOHLLQLT CACOUNT SQNQGENEQ SQNQGENEQ SQNQGENEQ SQNQGENEQ SQNQGENEQ SQNQGENEQ SQNQGENEQ DGERDKGRSE DGERDKGRSE DGERDKGRSE	WNDTELINGT NDTELINGT SSELYKYKVV RSELYKYKVV RSELYKYKVV RSELYKYKVV RSELYKYKVV RSELYKYKVV RSELYKYKVV RSELYKYKVV RSELYKYKVV SSELYKYKVV SSELYKYKVV SSELYKYKVV SSELYKYKVV SSELYKYKVV SSELYKYKVV SSELYKYKVV SSELYKYKVV SSELYKYKVV SSELYKYKVV SSELYKYKVV SSELYKYKVV SSELYKYKVV SSELYKYKVV SSELYKYVV SSELYKYKVV SSELYKYKVV SSELYKYKVV SSELYKYVV SSELYKYVV SSELYKYVV SSELYKYVV SSELYKYVV SSELYKVV SSELYKVV SSELYKVVV SSELYKVVV SSELYKVVV SSELYKVVV SSELYKVVV SSELYKVV SSELYKVV SSELYKVV SSELYKVVVV SSELYKVVVV SSELYKVVVV SSELYKVVVV SSELYKVVVV SSELYKVVVV SSELYKVVVV SSELYKVVVV SSELYKVVVV SSELYKVVVV SSELYKVVVV SSELYKVVVV SSELYKVVVV SSELYKVVVV SSELYKVVVV SSELYKVVVVV SSELYKVVVV SSELYKVVVV SSELYKVVVV SSELYKVVVV SSELYKVVVVV SSELYKVVVV SSELYKVVVVV SSELYKVVVVVVV SSELYKVVVVVV SSELYKVVVVVVVVVVVVVVVV	WNSTEGSDND I KIEPLGVAPT RIEPLGVAPT RIEPLGVAPT RIEPLGVAPT RIEPLGVAPT RIEPLGVAPT RIEPLGVAPT RIEPLGVAPT I VLAVERVIAD 0 600 I VLAVERVIAD 0 0 0 0 0 0 0 0 0 0 0 0 0	TIILPCRIRQ TIILPCRIRQ CARREVVORE EARREVVORE EARREVVORE EARREVVORE EARREVVORE EARREVVORE EARREVVORE EARREVVORE EARREVVORE EARREVVORE EARREVVORE EARREVVORE EARREVVORE EARREVVORE EARREV	IINRAQEVGR IINRAQEVGR KRAVGIGALF KRAVGIGALF KRAVGIGALF KRAVGIGALF KRAVGIGALF KRAVGIGALF KRAVGIGALF KRAVGIGALF KRAVGIGALF GKLICTAVP	AMYAPPIRGQ 540 1 LGFLGAAGST
Con C1. B 10042.205 10042.48 10042.101 10042.103 10042.205 Con C1. B 10042.48 10042.205 Con C1. B 10042.48 10042.205 Con C1. B 10042.48 10042.205 Con C1. B 10042.205	YGNNKTIVFK 460 IRCSSNITGL I	PHAGGDPEVE VI LLTRDGSN-N ILTRDGSN-S ILTRDGSNTS IL	RHIFNCGGEF ETEIFR ETKIDIETFR ETKIDIETFR ETKIDIETFR ETKIDIETFR ETKIDIETFR ETKIDIETFR ETKIDIETFR OQONNLERAI QQONNLERAI QQONNLERAI QQONNLERAI QQONNLERAI COONNLE	PYCHTTQLFT PGGDMDDNW PGGONMEDNW PGGONMEDNW PGGONMEDNW PGGONMEDNW PGGONMEDNW PGGONMEDNW PGGONMEDNW PGGONMEDNW PGGONMEDNW PGGONMEDNW PGGONMEDNW PGGONMEDNW PGGONMEDNW PGGONMEDNW PGGONMEDNW PGGONMEDNW PGGONMEDNW PGGONMEDNW PGGONMEDNW PGGENEGENEG SQNQGEKNEQ SQNQCEKNEQ SQNQCE	WNDTELINGT I RSELYKYKVV RSELYKYKVV RSELYKYKVV RSELYKYKVV RSELYKYKVV RSELYKYKVV RSELYKYKVV RSELYKYKVV RSELYKYKVV RSELYKYKVV P SSEY VWGIKOLOAR VWGIKOLOAR VWGIKOLOAR UWGIKOLOAR UWGIKOLOAR DUGLALOAN DLIALDKNDS DLIALDKNDS DLIALDKNDS DLIALDKNDS DLIALDKNDS DLIALDKNDS DLIALDKNDS DLIALDKNDS DLIALDKNDS DLIALDKNDS DLIALDKNDS DLIALDKNDS DLIALDKNDS DLIALDKNDS DLIALDKNDS DLIALDKNDS DLIALDKNDS RIVDGFIALI TLVEGFIALI TLVEGFIALI TLVEGFIALI TLVEGFIALI TLVEGFIALI TLVEGFIALI	WNSTEGSDND I KIEPLGVAPT RIEPLGVAPT RIEPLGVAPT RIEPLGVAPT RIEPLGVAPT RIEPLGVAPT RIEPLGVAPT RIEPLGVAPT RIEPLGVAPT I VLAVERVIAD 0 600 I VLAVERVIAD 0 600 I VLAVERVIAD 0 0 0 0 0 0 0 0 0 0 0 0 0	TIILPCRIRQ TIILPCRIRQ KAKRRVVQRE EAKRRVVQRE STRLEINGES SYMRLRDLLE SYMRLRDLE SYMR	IINRAQEVGR IINRAQEVGR KRAVGIGALF KRAVGIGALF KRAVGIGALF KRAVGIGALF KRAVGIGALF KRAVGIGALF KRAVGIGALF KRAVGIGALF GRLICTTAVP GKLICTTAVP GKLICTTAVP GKLICTTAVP GKLICTTAVP GKLICTTAVP GKLICTTAVP GKLICTTAVP GKLICTAVP GKLI	AMYAPPIRGQ 540 1 LGFLGAAGST

**Figure S3.** Full length gp160 amino acid alignment of the 'early' clones isolated from plasma that was collected approximately 19 years post infection. Representative Env clones were aligned with the consensus clade B sequence using Clustal W. The gp120, gp41 and signal peptide portions of Env are labeled, as are the variable loops V1-V5. Sites that are variable among the VC10042 clones are highlighted in yellow. Amino acid residues that are known to contact CD4 are marked with red circles and VRC01 are marked with blue circles.



**Figure S4.** Full length gp160 amino acid alignment of the 'late' clones isolated from plasma that was collected approximately 22 years post infection. Representative Env clones were aligned with the consensus clade B sequence using Clustal W. The gp120, gp41 and signal peptide portions of Env are labeled, as are the variable loops V1-V5. Sites that are variable among the clones from VC10042 are highlighted in yellow. Amino acid residues that are known to contact CD4 are marked with red circles and VRC01 are marked with blue circles.



**Figure S5. Phylogenetic tree** showing the relationship between the autologous *env* clones circulating in subject VC10042 at 19 years (A) and 22 years (B) post infection and *env* clones from heterologous isolates that were tested for their neutralization susceptibility of VC10042 plasma. Phylogenies were reconstructed using MEGA5.1(4) using Maximum Likelihood with 100 bootstrap replications, utilizing the Jones-Taylor-Thornton (JTT) substitution model and utilizing uniform rates. Bootstrap values are listed at each node and the scale bar is located in the bottom left. The potency with which the plasma is able to neutralize a given isolate is heat mapped, with non-neutralized isolates left uncolored, IC50 titers below 100 colored blue, IC50 titers between 100-250 colored in orange, and IC50 titers above 250 colored in red. (A) Neutralization with plasma isolated at 19 years post-infection.



**Figure S6**. The regions on gp120 that mediate escape from the neutralizing activity of the anti-CD4-BS NAbs in VC10042. Residues R373 and N386 reside outside the CD4 binding pocket (inset). All residues were mapped on to the HXB2 core molecule in the b12-bound state (2). Inset is slightly rotated to better view relevant features.



**Figure S7.** Neutralization sensitivity of the clone VC10042.y22.05 bearing reversion mutations to the monoclonal broadly neutralizing antibodies b12 (A), VRC01 (B), and NIH45-46<sup>G54W</sup> (C). Three reversion mutations were introduced into the wild type VC10042.y22.05 ( $\blacksquare$ ) clone: H364S( $\blacktriangle$ ), R373M ( $\bullet$ ), and N386D ( $\bullet$ ). A double mutant, H364s.R373M ( $\bullet$ ) was also generated.

## **References:**

- 1. Li, Y., S. A. Migueles, B. Welcher, K. Svehla, A. Phogat, M. K. Louder, X. Wu, G. M. Shaw, M. Connors, R. T. Wyatt, and J. R. Mascola. 2007. Broad HIV-1 neutralization mediated by CD4binding site antibodies. Nat Med 13:1032-4.
- 2. Liu, J., A. Bartesaghi, M. J. Borgnia, G. Sapiro, and S. Subramaniam. 2008. Molecular architecture of native HIV-1 gp120 trimers. Nature 455:109-13.
- 3. Sather, D. N., J. Armann, L. K. Ching, A. Mavrantoni, G. Sellhorn, Z. Caldwell, X. Yu, B. Wood, S. Self, S. Kalams, and L. Stamatatos. 2009. Factors associated with the development of crossreactive neutralizing antibodies during human immunodeficiency virus type 1 infection. J Virol 83:757-69.
- 4. Tamura, K., D. Peterson, N. Peterson, G. Stecher, M. Nei, and S. Kumar. 2011. MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. Mol Biol Evol 28:2731-9.